Insmed Inc
NASDAQ:INSM

Watchlist Manager
Insmed Inc Logo
Insmed Inc
NASDAQ:INSM
Watchlist
Price: 145.03 USD 0.19% Market Closed
Market Cap: 30.7B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one INSM stock under the Base Case scenario is 87.33 USD. Compared to the current market price of 145.03 USD, Insmed Inc is Overvalued by 40%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

INSM Relative Value
Base Case
87.33 USD
Overvaluation 40%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

76.9
P/S
P/S
Price to Sales
76.9
vs History
0
vs Industry
23
Median 3Y
13.7
Median 5Y
17.2
Industry
7.6
Forward
63.8
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-6.1
Median 5Y
-7.7
Industry
24.5
Forward
-25.9
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-7.9
Median 5Y
-9.1
Industry
21
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-18.5
Median 5Y
-18.5
Industry
23.5
More Details
24.5
P/B
P/B
Price to Book Value
24.5
vs History
28
vs Industry
1
Median 3Y
18.4
Median 5Y
11.2
Industry
3.1
More Details
73.7
EV/S
EV/S
Enterprise Value to Sales
73.7
vs History
0
vs Industry
19
Median 3Y
14.9
Median 5Y
16.3
Industry
8.1
Forward
61.1
More Details
97.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
97.3
vs History
0
vs Industry
15
Median 3Y
19.3
Median 5Y
20.8
Industry
10.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-7.2
Median 5Y
-8.8
Industry
5.7
Forward
-29.7
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-6.9
Median 5Y
-8.4
Industry
6.1
Forward
-28
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-8.6
Median 5Y
-9.1
Industry
7
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-8.4
Median 5Y
-8.9
Industry
5.3
More Details
53.8
EV/IC
EV/IC
Enterprise Value to IC
53.8
vs History
0
vs Industry
9
Median 3Y
9.5
Median 5Y
9.6
Industry
5.3
More Details

Multiples Across Competitors

INSM Competitors Multiples
Insmed Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Insmed Inc
NASDAQ:INSM
30.6B USD 76.9 -29.6 -32.1 -31.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 619 451.8 -159 788.3 -194 033.9 -191 819.8
US
Abbvie Inc
NYSE:ABBV
393.2B USD 6.7 105.6 17.2 25
US
Amgen Inc
NASDAQ:AMGN
153.9B USD 4.4 23.2 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
139.7B USD 4.8 22.1 10.3 14.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 095.5 -534.7 -582.2 -566.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
98.2B USD 8.6 27 19.8 20.7
AU
CSL Ltd
ASX:CSL
96.2B AUD 4.1 21.2 14.1 17.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
63.4B USD 4.5 14.2 12.8 14.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
60.1B USD 24.4 -188.4 -471.2 -323.4
US
Seagen Inc
F:SGT
39.3B EUR 20.2 -61.9 -66.7 -60.2
P/S Multiple
Revenue Growth P/S to Growth
US
Insmed Inc
NASDAQ:INSM
Average P/S: 3 056 518.4
76.9
77%
1
FR
Pharnext SCA
OTC:PNEXF
33 619 451.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.4
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
4%
1.2
US
E
Epizyme Inc
F:EPE
2 095.5
N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
8.6
10%
0.9
AU
CSL Ltd
ASX:CSL
4.1
6%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.5
5%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
24.4
41%
0.6
US
S
Seagen Inc
F:SGT
20.2
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Insmed Inc
NASDAQ:INSM
Average P/E: 35.6
Negative Multiple: -29.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -159 788.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
105.6
88%
1.2
US
Amgen Inc
NASDAQ:AMGN
23.2
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
22.1
191%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.7 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27
N/A N/A
AU
CSL Ltd
ASX:CSL
21.2
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.2
6%
2.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -188.4 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.9 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Insmed Inc
NASDAQ:INSM
Average EV/EBITDA: 15.4
Negative Multiple: -32.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 033.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.2
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.3
10%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
6%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -582.2 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
19.8
17%
1.2
AU
CSL Ltd
ASX:CSL
14.1
10%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.8
9%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -471.2 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Insmed Inc
NASDAQ:INSM
Average EV/EBIT: 18.4
Negative Multiple: -31.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -191 819.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.3
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.2
12%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.7 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.7
17%
1.2
AU
CSL Ltd
ASX:CSL
17.6
14%
1.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.4
12%
1.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -323.4 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.2 N/A N/A

See Also

Summary
INSM intrinsic value, competitors valuation, and company profile.
DCF Valuation
INSM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
INSM stock valuation using valuation multiples.
Wall Street Estimates
INSM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
INSM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 284,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.